Fig. 1From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibodyStudy design with overlapping SAD-MAD cohorts, where treatment periods took place in a staggered parallel manner. A cohort was initiated after review of the safety and PK data of the previous cohorts. SAD single ascending dose, MAD multiple ascending dose, PK pharmacokineticsBack to article page